Allogeneic

FDA Grants Regenerative Medicine Advanced Therapy (RMAT) Designation to AlloVir’s Posoleucel for Prevention of Multiple Life-Threatening Infections from Six Viruses in Allogeneic Hematopoietic Cell Transplant Patients

Anke Neustadt 7 months ago

Posoleucel’s third RMAT designation marks an unprecedented regulatory distinction among cell and gene therapies Global Phase 3 multi-virus prevention trial initiated in March 2022 and is enrolling patients WALTHAM, Mass., April 20, 2022–(BUSINESS WIRE)–AlloVir (Nasdaq: ALVR), a late clinical-stage allogeneic T cell immunotherapy company, today announced that the U.S. Food […]

Featured Post